DOI: https://doi.org/10.22141/2308-2097.2.56.2015.81502

Using the Quantitative Determination of HbsAg to Monitor Antiviral Therapy of Chronic HBV-Infection

I.A. Zaitsev

Abstract


Currently, the main unresolved issue in monitoring antiviral therapy of chronic HBV-infection is the lack of clear predictors of sustained virologic response to treatment. These predictors would allow early identification of non-responders to the treatment with pegylated interferon and prediction a high probability of preservation of response to the treatment with nucleos(t)id analogs, when the latter is stopped. The way out of this situation can be the use a quantitative assessment of HBsAg, and this review covers this problem.


Keywords


monitoring; chronic HBV-infection; HBsAg; antiviral therapy

References


Blumberg B.S., Alter H.J., Visnich S. A «new» antigen in leukemia sera // JAMA 1965; 191: 541-6.

Ganem D., Prince A.M. Hepatitis B virus infection-natural history and clinical consequences // N. Engl. J. Med. 2004; 350: 118-29.

Werle-Lapostolle B., Bowden S., Locarnini S. et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy // Gastroenterology 2004; 126: 1750-8.

Chan H.L., Wong V.W., Tse A.M. et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response // Clin. Gastroenterol. Hepatol. 2007; 5: 1462-8.

Jaroszewicz J., Calle Serrano B., Wursthorn K. et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective // J. Hepatol. 2010; 52: 514-22.

Martinot-Peignoux M., Lapalus M., Asselah T.A.D., Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome // Liver International 2014; 34 (Suppl. 1): 97-107.

Brunetto M.R., Moriconi F., Bononi F. et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B // Hepatology 2009; 49: 1141-50.

Moucari R., Mackiewicz V., Lada O. et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients // Hepatology 2009; 49: 1151-7.

Lok A.S.F., McMahon B.J. AASLD practice guideline update. Chronic hepatitis B: update 2009 // Hepatology 2009; 50: 1-36.

Liaw Y.F., Kao J.-H., Piratvisuth T. et al. Asian-Pacific consensus statements on the management of chronic hepatitis B: a 2012 update // Hepatol. Int. 2012; 6: 531-61.

EASL clinical practice guidelines: management of chronic hepatitis B European Association for the Study of the Liver // J. Hepatol. 2012; 50: 227-42.

Marcellin P., Gane R.J., Tsaui N. et al. Seven years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological response with no detectable resistance // Hepatology 2013: 58 (Suppl. 4): 649A.

Marcellin P., Curescu M.G., Piekarska A. et al. Outcome of treatment with peginterferon alfa 2a (40KD) in HBeAg positive and HBeAg negative patients with chronic hepatitis B (CHB) in the real-world study: interim analysis of data from the large European S-collate cohort // Hepatology 2013; 58 (Suppl. 4): 656A.

Gane E., Jia J., Han K., Tanwandee T., Chuang W.L., Chu-ang W.L. et al. Neptune study: on-treatment HBsAg level analysis confirms prediction of response observed in phase 3 study of peginterferon alfa-2a in HBeAg-positive patients // J. Hepatol. 2011; 54: S31.

Liaw Y.F., Jia J.D., Chan H.L.Y. et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior HBeAg seroconversion rates in HBV genotypes B or C // Hepatology 2011; 54: 1591-1599.

Piratvisuth T., Marcellin P., Popescu M., Kapprell H.P., Rothe V., Lu Z.M. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients // Hepatol. Int. 2011, Jun 24. [Epub ahead of print].

Bonino F., Marcellin P., Lau G.K., Hadziyannis S., Jin R., Piratvisuth T. et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B // Gut 2007; 56: 699-705.

Rijckborst V., Hansen B.E., Cakaloglu Y., Ferenci P., Tabak F., Akdogan M. et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels // Hepatology 2010; 52: 454-461.

Rijckborst V., Hansen B.E., Ferenci P., Brunetto M.R., Tabak F., Cakaloglu Y. et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a // J. Hepatol. 2012; 56: 1006-1011.

Chan H.L., Wong V.W., Chim A.M. et al. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B // Aliment. Pharmacol. Ther. 2010; 32: 1323-315.

Gane E., Jia J., Han K. et al. NEPTUNE study; on treatment HBsAg level analysis confirms prediction of response observed in phase 3 study of peginterferon alfa-2a in HBeAg positive patients // J. Hepatol. 2011; 58 (4, Suppl.): 656A. Abstract 69.

Sonneveld M.J., Rijckborst V., Boucher C.A. et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline // Hepatology 2010; 52: 1251-7.

Moucari R., Martinot-Peignoux M., Mackiewicz V. et al. Influence of genotype on hepatitis B surafce antigen in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha-2a // Antivir. Ther. 2009; 14: 1183-8.

Brunetto M.R., Marcellin P., Cherubin B. et al. Response to peginterferon alfa-2a(40KD) in HBeAg-negative CHB: on treatment kinetics of HBsAg serum levels vary by HBV genotype // J. Hepatol. 2013; 59: 1153-9.

Soneveld M.J., Rijckborst V., Cakalog Y. et al. Durable hepatitis surface antigen decline in hepatitis B e antigen positive chronic hepatitis B patients treated with pegylated interferon-a2b: relation to response and HBV genotype // Antivir. Ther. 2012; 17: 9-17.

Тer Borg M.J., van Zonneveld M., Zeuzem S. et al. Patterns of viral decline during PEG-Interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response // Hepatology 2006; 44: 721-7.

Marcellin P., Bonino F., Yurdayin C. et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e antigen-negative patients // Hepatol. Int. 2013; 7: 88-97.

Moucari R., Korevaar A., Lada O. et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study // J. Hepatol. 2009; 50: 1084-92.

Lee J.M., Ahn S.H., Kim H.S. et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir // Hepatology 2010; 53: 1486-93.

Orito E., Fujiwara K., Kanie H. et al. Quantification of HBsAg predicts response to entecavir therapy in HBV genotype C patients // World J. Gastroenterol. 2012; 18: 5570-5.

Seto W.K., Wong D.K.H., Fung J. et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy // Hepatology 2013; 58: 923-31.

Lee M.H., Lee D.M., Kim S.S. et al. Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B // J. Med. Virol. 2011; 83: 1178-86.

Wang C.C., Tseng T.C., Wag P.C. et al. Baseline hepatitis B surface antigen quantification can predict virologic response in entecavir treated chronic hepatitis B patients // Journal of Formosan Medical Association 2013; 112: 1-8.

Zeuzem S., Gane E., Liaw Y.F. et al. Baseline characteristics and early on treatment response predict the outcomes of 2 years of telbuvidine treatment of chronic hepatitis B // J. Hepatol. 2009; 51: 11-20.

Peng C.Y., Hsieh T.C., Hsieh T.Y. et al. HBV-DNA level at 6 months of entecavir treatment predicts HBe loss in HBeAg positive chronic hepatitis B patients // J. Formosan Med. Assoс. 2013; 112: 1-6.

Keefe E.B., Zeuzem S., Kokk R. et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B // Clinical Gastroenterol. Hepatol. 2007; 5: 890-7.

Chan H.L., Thompson A., Martinot-Peignoux M. et al. Hepatitis B surface antigen quantification: Why and how to use it in 2011 — а core group report // Journal of Hepatology 2011; 55: 1121-1131.

Heathcote E.J., Marcellin M., Buti M. et al. Three years efficacy and safety of tenofovir disiproxil fumarate treatment for chronic hepatitis B // Gastroenterology 2011; 140: 132-43.

Marcellin M., Heathcote E.J., Buti M. et al. Tenofovir di-siproxil fumarate versus adefovir dipivoxil for chronic hepatitis B // N. Engl. J. Med. 2008; 359: 2442-55.

Gish R.G., Chang T.T., Lai C.L. et al. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive, nucleoside-naпve patients treated with entecavir // Antiviral Therapy 2013; 18: 691-8.

Li M.R., Xi H.L., Wang Q.H. et al. Kinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis B // PLOS-one 2014; 9: e98476.

Fung J., Lai C.L., Young J. et al. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment // Am. J. Gastroenterol. 2011; 106: 1766-1773.

Marcellin P., Buti M., Krastev Z. et al. Kinetics of hepatitis B surface antigen loss in patients with HBe-Ag positive chronic hepatitis B treated with tenofovir disoproxil fumarate // J. Hepatol. 2014; 61: 12228-37.

Wursthorn K., Jung M., Riva A. et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients // Hepatology 2010; 52: 1611-20.

Boglione L., Cardellino C.S., de Nicolo A. et al. Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg negative genotype A, D, and E // J. Med. Virol. 2014; 86: 1845-50.

Chan H.L., Wong G.L., Chim A.M. et al. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients // Antivir. Ther. 2011; 16: 1249-1257.

Kim S.S., Lee D., Lee M.H. et al. Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B // Hepatology Research 2013; 13: 219-27.

Chang T.T., Gish R.G., de Man R. et al. A comparison of entecavir and lamivudine for HBeAg positive chronic hepatitis B // N. Engl. J. Med. 2006; 354: 1001-10.

Chen C.H., Lu S.N., Hung C.H. et al. The role of hepatitis B surface antigen quantification in predicting HBSAg loss and HBv relapse after discontinuation of lamuvidine treatment // J. Hepatol. 2014; 61: 515-22.

Cai W., Xie Q., An B. et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients // J. Clin. Virol. 2010; 48: 22-26.

Liang Y., Jiang J., Su M. et al. Predictors of relapse in chronic hepatitis B after discontinuation of antiviral therapy // Aliment. Pharmacol. Ther. 2011; 34: 344-52.




Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта